ClinicalTrials.gg

Program

elenestinib

Also written as “Elenestinib” and “BLU-263”.

In Sanofi's pipeline, D816V-mutated KIT inhibitor. Its studies are mostly in Mastocytosis, Systemic, led by Sanofi.

Furthest: phase 3, since May 17, 20213 company-led studies, 1 open or runningNext primary completion: Sep 30, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi31 open or runningphase 3since May 17, 2021May 17, 2021Sep 30, 2032phase 3 · NCT04910685
  • Named in Sanofi’s own pipeline as elenestinib, phase 3, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2021First study: phase 3 study in Mastocytosis, SystemicFirst studyNCT04910685 · 534 planned · United States, Argentina, Australia and more
  2. Nov 2, 2022Phase 1 study in Mastocytosis, SystemicNCT05609942 · 9 enrolled · United States, Belgium, France and more
  3. Jan 29, 2026Phase 1 study in Healthy ParticipantsNCT07388511 · 20 enrolled · United States

Ahead

  1. Sep 30, 2032Primary completion: phase 3 study in Mastocytosis, SystemicNCT04910685

TargetBeta

“D816V-mutated KIT inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable protein tyrosine kinase inhibitor of the mutated form of the tumor-associated antigen (TAA) mast/stem cell factor receptor c-Kit (SCFR), D816V, with potential antineoplastic activity. Upon oral administration, elenestinib binds to and inhibits the specific c-Kit mutant D816…”NCIt, read by Claude
“An orally bioavailable protein tyrosine kinase inhibitor of the mutated form of the tumor-associated antigen (TAA) mast/stem cell factor receptor c-Kit (SCFR), D816V, ”NCIt, by rule

Other programs on KIT

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
anlotinibruleSino Biopharmaceuticalphase 340
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
velzatinibGlaxoSmithKlinephase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
NB-003ruleningbo-newbay-technology-development-co-ltdphase 32
briquilimabrulejasper-therapeutics-incphase 27
BLU-808Sanofiphase 23

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07388511Healthy Participants · United States1CompletedApr 2, 202620
NCT05609942Mastocytosis, Systemic · United States, Belgium, France and more1TerminatedJan 14, 20259
NCT04910685Mastocytosis, Systemic · United States, Argentina, Australia and more3RecruitingSep 30, 2032534

How it is read

Names in the registry

  • “Elenestinib”, 2 entries
  • “BLU-263”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.